Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-11-16

AUTHORS

Shuang Zhao, Shangying Hu, Xiaoqian Xu, Xun Zhang, Qinjing Pan, Feng Chen, Fanghui Zhao

ABSTRACT

BackgroundIt is widely acknowledged that HPV prophylactic vaccine could prevent new infections and their associated lesions among women who are predominantly HPV-naive at vaccination. Yet there still remains uncertainty about whether HPV vaccination could benefit to individuals who have undergone surgery for cervical disease.MethodsThis post-hoc analysis intends to focus on intent-to-treat participants who underwent excision treatment at baseline and the follow-up period in a phase II/III, double-blind, randomized trial (ClinicalTrials.gov, number NCT00779766) conducted in Jiangsu province, China. We evaluate the impact of HPV vaccination on preventing women from subsequent infection and cervical lesions (LSIL+ and CIN2+) after excision treatment.ResultsOne hundred sixty-eight (vaccine, n = 87; placebo, n = 81) performed excisional treatment in this clinical trial. We observed a significant effect of vaccination on acquiring 14 high-risk HPV (HR-HPV) infection after treatment (vaccine efficacy: 27.0%; 95% CI 4.9, 44.0%). The vaccine efficacy against new infections after treatment for 14 HR-HPV infection was estimated as 32.0% (95%CI 1.8, 52.8%), and was 41.2% (95%CI -162.7, 86.8%) for HPV16/18 infection. The accumulative clearance rates of the vaccine group and placebo group were 88.9 and 81.6% for HPV16/18 infection (P = 0.345), 63.4, 48.7% for 14 HR-HPV infection (P = 0.062), respectively. No significant difference was observed on the persistent rate of HPV16/18, 14 HR-HPV infection and occurrence rate of LSIL+ between the two groups.ConclusionsNo significant evidence from this study showed that HPV-16/18 AS04-adjuvanted vaccine could lead to viral faster clearance or have any effect on the rates of persistent infection among women who had excision treatment. However, the vaccine may still benefit post-treatment women with “primary prophylactic” effect. Further research is required in clarifying the effect of using the prophylactic HPV vaccine as therapeutic agents.Trial registrationClinicalTrials.gov identifier: NCT00779766. Date and status of trial registration: October 24, 2008. Completed; Has Results. More... »

PAGES

846

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12879-020-05560-z

DOI

http://dx.doi.org/10.1186/s12879-020-05560-z

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1132651360

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33198657


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1107", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Immunology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adjuvants, Immunologic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cervical Intraepithelial Neoplasia", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "China", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Double-Blind Method", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Human papillomavirus 16", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Human papillomavirus 18", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Papillomavirus Infections", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Papillomavirus Vaccines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Uterine Cervical Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Vaccination", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhao", 
        "givenName": "Shuang", 
        "id": "sg:person.0671022567.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671022567.52"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hu", 
        "givenName": "Shangying", 
        "id": "sg:person.016554470547.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554470547.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xu", 
        "givenName": "Xiaoqian", 
        "id": "sg:person.014525467523.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014525467523.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cytology and Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Department of Cytology and Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Xun", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cytology and Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Department of Cytology and Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pan", 
        "givenName": "Qinjing", 
        "id": "sg:person.0602207426.93", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602207426.93"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Chen", 
        "givenName": "Feng", 
        "id": "sg:person.01252261432.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252261432.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China", 
          "id": "http://www.grid.ac/institutes/grid.506261.6", 
          "name": [
            "Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhao", 
        "givenName": "Fanghui", 
        "id": "sg:person.01000555677.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000555677.13"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00404-020-05740-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1130155349", 
          "https://doi.org/10.1007/s00404-020-05740-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-11-16", 
    "datePublishedReg": "2020-11-16", 
    "description": "BackgroundIt is widely acknowledged that HPV prophylactic vaccine could prevent new infections and their associated lesions among women who are predominantly HPV-naive at vaccination. Yet there still remains uncertainty about whether HPV vaccination could benefit to individuals who have undergone surgery for cervical disease.MethodsThis post-hoc analysis intends to focus on intent-to-treat participants who underwent excision treatment at baseline and the follow-up period in a phase II/III, double-blind, randomized trial (ClinicalTrials.gov, number NCT00779766) conducted in Jiangsu province, China. We evaluate the impact of HPV vaccination on preventing women from subsequent infection and cervical lesions (LSIL+ and CIN2+) after excision treatment.ResultsOne hundred sixty-eight (vaccine, n\u2009=\u200987; placebo, n\u2009=\u200981) performed excisional treatment in this clinical trial. We observed a significant effect of vaccination on acquiring 14 high-risk HPV (HR-HPV) infection after treatment (vaccine efficacy: 27.0%; 95% CI 4.9, 44.0%). The vaccine efficacy against new infections after treatment for 14 HR-HPV infection was estimated as 32.0% (95%CI 1.8, 52.8%), and was 41.2% (95%CI -162.7, 86.8%) for HPV16/18 infection. The accumulative clearance rates of the vaccine group and placebo group were 88.9 and 81.6% for HPV16/18 infection (P\u2009=\u20090.345), 63.4, 48.7% for 14 HR-HPV infection (P\u2009=\u20090.062), respectively. No significant difference was observed on the persistent rate of HPV16/18, 14 HR-HPV infection and occurrence rate of LSIL+ between the two groups.ConclusionsNo significant evidence from this study showed that HPV-16/18 AS04-adjuvanted vaccine could lead to viral faster clearance or have any effect on the rates of persistent infection among women who had excision treatment. However, the vaccine may still benefit post-treatment women with \u201cprimary prophylactic\u201d effect. Further research is required in clarifying the effect of using the prophylactic HPV vaccine as therapeutic agents.Trial registrationClinicalTrials.gov identifier: NCT00779766. Date and status of trial registration: October 24, 2008. Completed; Has Results.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12879-020-05560-z", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024946", 
        "issn": [
          "1471-2334"
        ], 
        "name": "BMC Infectious Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "20"
      }
    ], 
    "keywords": [
      "HR-HPV infection", 
      "HPV-16/18 AS04", 
      "Post Hoc Analysis", 
      "HPV vaccination", 
      "HPV16/18 infection", 
      "subsequent infection", 
      "new infections", 
      "high-risk HPV infection", 
      "phase II/III", 
      "HPV prophylactic vaccines", 
      "prophylactic HPV vaccines", 
      "excision treatment", 
      "ResultsOne hundred sixty", 
      "excisional treatment", 
      "HPV infection", 
      "vaccine group", 
      "placebo group", 
      "HPV vaccine", 
      "cervical disease", 
      "prophylactic vaccines", 
      "randomized trials", 
      "TRIAL REGISTRATION", 
      "cervical lesions", 
      "vaccine efficacy", 
      "treat participants", 
      "clinical trials", 
      "persistent infection", 
      "vaccination", 
      "vaccine", 
      "infection", 
      "clearance rate", 
      "therapeutic agents", 
      "fast clearance", 
      "women", 
      "persistent rate", 
      "trials", 
      "AS04", 
      "treatment", 
      "significant differences", 
      "lesions", 
      "disease", 
      "occurrence rate", 
      "group", 
      "further research", 
      "HPV16/18", 
      "HPV", 
      "surgery", 
      "BackgroundIt", 
      "baseline", 
      "clearance", 
      "significant effect", 
      "efficacy", 
      "rate", 
      "significant evidence", 
      "effect", 
      "status", 
      "participants", 
      "agents", 
      "individuals", 
      "evidence", 
      "period", 
      "differences", 
      "study", 
      "Jiangsu Province", 
      "intent", 
      "impact", 
      "date", 
      "analysis", 
      "sixties", 
      "registration", 
      "results", 
      "Province", 
      "identifiers", 
      "research", 
      "China", 
      "uncertainty"
    ], 
    "name": "Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial", 
    "pagination": "846", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1132651360"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12879-020-05560-z"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33198657"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12879-020-05560-z", 
      "https://app.dimensions.ai/details/publication/pub.1132651360"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T16:05", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_868.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12879-020-05560-z"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12879-020-05560-z'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12879-020-05560-z'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12879-020-05560-z'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12879-020-05560-z'


 

This table displays all metadata directly associated to this object as RDF triples.

243 TRIPLES      21 PREDICATES      117 URIs      108 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12879-020-05560-z schema:about N04b293347ca54a4eb30b8fbe4d397233
2 N07626d83379b4b85945c38ccf4593ab9
3 N0e7ac593265e4eea94e92bcc1956e59c
4 N29a9f9b13cf9426c98ecf10942458718
5 N2adeb25f35e74bfea87c6a4f45336a85
6 N377b1fd957dd4c9fa9f7fdf601b71fa7
7 N4ebf3da4bad44148b8a244cd5e5364a0
8 N5bd95624c6294649af75a1a2d426c3db
9 N69755b7908aa4ccfb58aaaed686f5efb
10 N6f56acade57f45daa5820a2a6b270182
11 N710fc0fe7b98457d81d268294938441b
12 N8c118ebf041f45fea87bd8ddfca304a7
13 Nbfe71c6dd5094324b5b9b0f979bcb6dd
14 Nc77429bb0f8f491c82715b42148e7790
15 Nf77f2ee031334caebc19428afa2989b8
16 anzsrc-for:11
17 anzsrc-for:1107
18 schema:author N2035f94d6ea94194b3e423502dc98982
19 schema:citation sg:pub.10.1007/s00404-020-05740-x
20 schema:datePublished 2020-11-16
21 schema:datePublishedReg 2020-11-16
22 schema:description BackgroundIt is widely acknowledged that HPV prophylactic vaccine could prevent new infections and their associated lesions among women who are predominantly HPV-naive at vaccination. Yet there still remains uncertainty about whether HPV vaccination could benefit to individuals who have undergone surgery for cervical disease.MethodsThis post-hoc analysis intends to focus on intent-to-treat participants who underwent excision treatment at baseline and the follow-up period in a phase II/III, double-blind, randomized trial (ClinicalTrials.gov, number NCT00779766) conducted in Jiangsu province, China. We evaluate the impact of HPV vaccination on preventing women from subsequent infection and cervical lesions (LSIL+ and CIN2+) after excision treatment.ResultsOne hundred sixty-eight (vaccine, n = 87; placebo, n = 81) performed excisional treatment in this clinical trial. We observed a significant effect of vaccination on acquiring 14 high-risk HPV (HR-HPV) infection after treatment (vaccine efficacy: 27.0%; 95% CI 4.9, 44.0%). The vaccine efficacy against new infections after treatment for 14 HR-HPV infection was estimated as 32.0% (95%CI 1.8, 52.8%), and was 41.2% (95%CI -162.7, 86.8%) for HPV16/18 infection. The accumulative clearance rates of the vaccine group and placebo group were 88.9 and 81.6% for HPV16/18 infection (P = 0.345), 63.4, 48.7% for 14 HR-HPV infection (P = 0.062), respectively. No significant difference was observed on the persistent rate of HPV16/18, 14 HR-HPV infection and occurrence rate of LSIL+ between the two groups.ConclusionsNo significant evidence from this study showed that HPV-16/18 AS04-adjuvanted vaccine could lead to viral faster clearance or have any effect on the rates of persistent infection among women who had excision treatment. However, the vaccine may still benefit post-treatment women with “primary prophylactic” effect. Further research is required in clarifying the effect of using the prophylactic HPV vaccine as therapeutic agents.Trial registrationClinicalTrials.gov identifier: NCT00779766. Date and status of trial registration: October 24, 2008. Completed; Has Results.
23 schema:genre article
24 schema:isAccessibleForFree true
25 schema:isPartOf N6db0c94f95004416adc835792189f7f5
26 N92b5fbbe7e62483ea23bb3517f523d04
27 sg:journal.1024946
28 schema:keywords AS04
29 BackgroundIt
30 China
31 HPV
32 HPV infection
33 HPV prophylactic vaccines
34 HPV vaccination
35 HPV vaccine
36 HPV-16/18 AS04
37 HPV16/18
38 HPV16/18 infection
39 HR-HPV infection
40 Jiangsu Province
41 Post Hoc Analysis
42 Province
43 ResultsOne hundred sixty
44 TRIAL REGISTRATION
45 agents
46 analysis
47 baseline
48 cervical disease
49 cervical lesions
50 clearance
51 clearance rate
52 clinical trials
53 date
54 differences
55 disease
56 effect
57 efficacy
58 evidence
59 excision treatment
60 excisional treatment
61 fast clearance
62 further research
63 group
64 high-risk HPV infection
65 identifiers
66 impact
67 individuals
68 infection
69 intent
70 lesions
71 new infections
72 occurrence rate
73 participants
74 period
75 persistent infection
76 persistent rate
77 phase II/III
78 placebo group
79 prophylactic HPV vaccines
80 prophylactic vaccines
81 randomized trials
82 rate
83 registration
84 research
85 results
86 significant differences
87 significant effect
88 significant evidence
89 sixties
90 status
91 study
92 subsequent infection
93 surgery
94 therapeutic agents
95 treat participants
96 treatment
97 trials
98 uncertainty
99 vaccination
100 vaccine
101 vaccine efficacy
102 vaccine group
103 women
104 schema:name Impact of HPV-16/18 AS04-adjuvanted vaccine on preventing subsequent infection and disease after excision treatment: post-hoc analysis from a randomized controlled trial
105 schema:pagination 846
106 schema:productId N8455edb38bc04cd7a1c37365c28db9d3
107 Na4f9993b0ff54d9aa39a781b7b11a6cb
108 Nc5f43a9668984ffca47eb4b4b4f55fc4
109 schema:sameAs https://app.dimensions.ai/details/publication/pub.1132651360
110 https://doi.org/10.1186/s12879-020-05560-z
111 schema:sdDatePublished 2022-09-02T16:05
112 schema:sdLicense https://scigraph.springernature.com/explorer/license/
113 schema:sdPublisher Na2b7a4d2a066411eaef04315456bbe6b
114 schema:url https://doi.org/10.1186/s12879-020-05560-z
115 sgo:license sg:explorer/license/
116 sgo:sdDataset articles
117 rdf:type schema:ScholarlyArticle
118 N04b293347ca54a4eb30b8fbe4d397233 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Papillomavirus Infections
120 rdf:type schema:DefinedTerm
121 N07626d83379b4b85945c38ccf4593ab9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Adult
123 rdf:type schema:DefinedTerm
124 N0868bfd8837042dea8e5e83a239b0683 rdf:first Na1faea7aa53b4a628734dccd865139c8
125 rdf:rest N859a61751d46416a82d1278270330787
126 N0e7ac593265e4eea94e92bcc1956e59c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Uterine Cervical Neoplasms
128 rdf:type schema:DefinedTerm
129 N2035f94d6ea94194b3e423502dc98982 rdf:first sg:person.0671022567.52
130 rdf:rest N3c989419ad454f36a4ff190ce5d1668c
131 N29a9f9b13cf9426c98ecf10942458718 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Papillomavirus Vaccines
133 rdf:type schema:DefinedTerm
134 N2adeb25f35e74bfea87c6a4f45336a85 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Humans
136 rdf:type schema:DefinedTerm
137 N377b1fd957dd4c9fa9f7fdf601b71fa7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Human papillomavirus 18
139 rdf:type schema:DefinedTerm
140 N3c989419ad454f36a4ff190ce5d1668c rdf:first sg:person.016554470547.46
141 rdf:rest N66f7151497be4f079f75e0813bcf6119
142 N4ebf3da4bad44148b8a244cd5e5364a0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Human papillomavirus 16
144 rdf:type schema:DefinedTerm
145 N5bd95624c6294649af75a1a2d426c3db schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Cervical Intraepithelial Neoplasia
147 rdf:type schema:DefinedTerm
148 N66f7151497be4f079f75e0813bcf6119 rdf:first sg:person.014525467523.08
149 rdf:rest N0868bfd8837042dea8e5e83a239b0683
150 N69755b7908aa4ccfb58aaaed686f5efb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Female
152 rdf:type schema:DefinedTerm
153 N6db0c94f95004416adc835792189f7f5 schema:volumeNumber 20
154 rdf:type schema:PublicationVolume
155 N6f56acade57f45daa5820a2a6b270182 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Follow-Up Studies
157 rdf:type schema:DefinedTerm
158 N710fc0fe7b98457d81d268294938441b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Vaccination
160 rdf:type schema:DefinedTerm
161 N8455edb38bc04cd7a1c37365c28db9d3 schema:name doi
162 schema:value 10.1186/s12879-020-05560-z
163 rdf:type schema:PropertyValue
164 N859a61751d46416a82d1278270330787 rdf:first sg:person.0602207426.93
165 rdf:rest Nb1148c01e2d646b8b2d9c86505941977
166 N8c118ebf041f45fea87bd8ddfca304a7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Double-Blind Method
168 rdf:type schema:DefinedTerm
169 N92b5fbbe7e62483ea23bb3517f523d04 schema:issueNumber 1
170 rdf:type schema:PublicationIssue
171 Na1faea7aa53b4a628734dccd865139c8 schema:affiliation grid-institutes:grid.506261.6
172 schema:familyName Zhang
173 schema:givenName Xun
174 rdf:type schema:Person
175 Na2b7a4d2a066411eaef04315456bbe6b schema:name Springer Nature - SN SciGraph project
176 rdf:type schema:Organization
177 Na4f9993b0ff54d9aa39a781b7b11a6cb schema:name dimensions_id
178 schema:value pub.1132651360
179 rdf:type schema:PropertyValue
180 Nb1148c01e2d646b8b2d9c86505941977 rdf:first sg:person.01252261432.20
181 rdf:rest Nba88c963f7bd4787ac4c81e051fa8a5f
182 Nba88c963f7bd4787ac4c81e051fa8a5f rdf:first sg:person.01000555677.13
183 rdf:rest rdf:nil
184 Nbfe71c6dd5094324b5b9b0f979bcb6dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name China
186 rdf:type schema:DefinedTerm
187 Nc5f43a9668984ffca47eb4b4b4f55fc4 schema:name pubmed_id
188 schema:value 33198657
189 rdf:type schema:PropertyValue
190 Nc77429bb0f8f491c82715b42148e7790 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
191 schema:name Adjuvants, Immunologic
192 rdf:type schema:DefinedTerm
193 Nf77f2ee031334caebc19428afa2989b8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Adolescent
195 rdf:type schema:DefinedTerm
196 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
197 schema:name Medical and Health Sciences
198 rdf:type schema:DefinedTerm
199 anzsrc-for:1107 schema:inDefinedTermSet anzsrc-for:
200 schema:name Immunology
201 rdf:type schema:DefinedTerm
202 sg:journal.1024946 schema:issn 1471-2334
203 schema:name BMC Infectious Diseases
204 schema:publisher Springer Nature
205 rdf:type schema:Periodical
206 sg:person.01000555677.13 schema:affiliation grid-institutes:grid.506261.6
207 schema:familyName Zhao
208 schema:givenName Fanghui
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01000555677.13
210 rdf:type schema:Person
211 sg:person.01252261432.20 schema:affiliation grid-institutes:grid.506261.6
212 schema:familyName Chen
213 schema:givenName Feng
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01252261432.20
215 rdf:type schema:Person
216 sg:person.014525467523.08 schema:affiliation grid-institutes:grid.506261.6
217 schema:familyName Xu
218 schema:givenName Xiaoqian
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014525467523.08
220 rdf:type schema:Person
221 sg:person.016554470547.46 schema:affiliation grid-institutes:grid.506261.6
222 schema:familyName Hu
223 schema:givenName Shangying
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016554470547.46
225 rdf:type schema:Person
226 sg:person.0602207426.93 schema:affiliation grid-institutes:grid.506261.6
227 schema:familyName Pan
228 schema:givenName Qinjing
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0602207426.93
230 rdf:type schema:Person
231 sg:person.0671022567.52 schema:affiliation grid-institutes:grid.506261.6
232 schema:familyName Zhao
233 schema:givenName Shuang
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0671022567.52
235 rdf:type schema:Person
236 sg:pub.10.1007/s00404-020-05740-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1130155349
237 https://doi.org/10.1007/s00404-020-05740-x
238 rdf:type schema:CreativeWork
239 grid-institutes:grid.506261.6 schema:alternateName Department of Cytology and Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
240 Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China
241 schema:name Department of Cytology and Pathology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 100021, Beijing, China
242 Department of Epidemiology, National Cancer Center/ National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, 17 South Panjiayuan Lane, PO Box 2258, 100021, Beijing, China
243 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...